Omeros Corporation
$ 11.84
-0.75%
31 Jul - close price
- Market Cap 863,438,000 USD
- Current Price $ 11.84
- High / Low $ 11.99 / 11.37
- Stock P/E 10.20
- Book Value -0.88
- EPS 1.17
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -5.76 %
- 52 Week High 17.65
- 52 Week Low 3.44
About
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies, and orphan indications targeting inflammation, complement-mediated diseases, central nervous system (CNS) disorders, and system-related diseases. immunological. The company is headquartered in Seattle, Washington.
Analyst Target Price
$33.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-31 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-13 | 2024-08-07 | 2024-04-01 | 2024-03-26 | 2023-11-09 | 2023-08-09 |
| Reported EPS | 0.57 | -0.5464 | -0.32 | -0.53 | -0.65 | -0.55 | -0.64 | -1.12 | -0.75 | -0.15 | -0.82 | -0.7 |
| Estimated EPS | -0.39 | -0.5202 | -0.48 | -0.55 | -0.58 | -0.71 | -0.77 | -1.01 | -0.63 | -0.55 | -0.66 | -0.53 |
| Surprise | 0.96 | -0.0262 | 0.16 | 0.02 | -0.07 | 0.16 | 0.13 | -0.11 | -0.12 | 0.4 | -0.16 | -0.17 |
| Surprise Percentage | 246.1538% | -5.0365% | 33.3333% | 3.6364% | -12.069% | 22.5352% | 16.8831% | -10.8911% | -19.0476% | 72.7273% | -24.2424% | -32.0755% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMER
2026-07-30 00:10:01
This article provides details on Omeros Corporation's (HAM:3O8) financials, specifically its revenue breakdown. It lists various sections available on TradingView for the company, including an overview, financial statements, statistics, dividends, earnings, and segment performance. The content is primarily navigational and informational regarding what financial data points are accessible for Omeros Corporation on the platform.
2026-07-29 19:10:01
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,961,792 shares of Omeros Corp common stock, which represents an 8.2% stake in the company. BlackRock exercises sole voting power over 5,835,368 shares and sole dispositive power over all 5,961,792 shares, with no single client holding more than five percent of Omeros's outstanding common stock. This filing indicates that the shares are held for investment purposes in the ordinary course of business, rather than to influence control of the issuer.
2026-07-29 01:09:39
Pomerantz LLP is investigating Omeros Corporation for securities fraud following a significant 19.12% stock drop on June 26, 2026. This decline occurred after the European Medicines Agency issued a negative opinion regarding Omeros's drug narsoplimab. The investigation seeks to determine if Omeros misled investors about the drug's approval prospects, and affected investors are encouraged to contact the law firm.
2026-07-28 14:10:02
TradingKey provides a comprehensive stock analysis for Omeros Corp (OMER), noting its stable fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The company, focused on developing therapeutics for immunologic disorders and cancers, has high institutional ownership and four analysts recommending a "Buy" with a high target price. However, the analysis also indicates an expected downward trend in the medium term and sideways trading, making it suitable for range-bound swing trading.
2026-07-27 13:42:39
This page provides financial information for Omeros Corporation (LS:A0NBFF) on TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment breakdowns by source and country. The content appears to be a stub or a section of a larger financial data platform.
2026-07-27 12:25:00
H.C. Wainwright reiterated its 'Buy' rating on Omeros (OMER) after AstraZeneca's (AZN) Ultomiris failed its primary endpoint in a Phase 3 trial for transplant-associated thrombotic microangiopathy (TA-TMA). This setback is seen as a "clear positive" for Omeros, as it removes the primary near-term competitive threat to its FDA-approved drug, Yartemlea, improving its competitive positioning in the U.S. market, despite earlier European regulatory hurdles for Yartemlea.
